Zhiyan Xu

Zhiyan Xu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2018 in Molecular Brain
Verified
Journal Article
Open access
PDF file
DBDale B. Bosco
Dale B. Bosco
JZJIAYING ZHENG
JIAYING ZHENG
ZXZhiyan Xu
Zhiyan Xu
JPJiyun Peng
Jiyun Peng
UEUkpong B. Eyo
Ukpong B. Eyo
LWLong-Jun Wu
Long-Jun Wu
Microglia have been shown to be of critical importance to the progression of temporal lobe epilepsy. However, the broad transcriptional changes that these cells undergo following seizure induction is not well understood. As such, we utilized RNAseq analysis upon microglia isolated from the hippocampus to determine expression pattern alterations following kainic acid induced seizure. We determined that microglia undergo dramatic changes to their expression patterns, particularly with regard to mitochondrial activity and metabolism. We also observed that microglia initiate immunological activity, specifically increasing interferon beta responsiveness. Our results provide novel insights into microglia transcriptional regulation following acute seizures and suggest potential therapeutic targets specifically in microglia for the treatment of seizures and epilepsy.

10 October 2023 in Neuron
Verified
Journal Article
Closed access
MSMinjie Shen
Minjie Shen
CSCarissa L. Sirois
Carissa L. Sirois
YGYu Guo
Yu Guo
MLMeng Li
Meng Li
QDQiping Dong
Qiping Dong
XZXinyu Zhao
Xinyu Zhao

1 March 2022 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
CZChangliang Zhang
Changliang Zhang
YZYu Zhang
Yu Zhang
KMKai Ma
Kai Ma
GWGuangxian Wang
Guangxian Wang
MTMin Tang
Min Tang
HWHui Wang
Hui Wang
Background: Functional constipation (FC) is a common gastrointestinal (GI) disorder characterized by symptoms of constipation without a clear physiologic or anatomic cause. Gut microbiome dysbiosis has been postulated to be a factor in the development of FC, and treatment with probiotic regimens, including strains of Lactobacillus plantarum (L. plantarum), has demonstrated efficacy in managing symptoms. To further understand the role of L. plantarum in GI health, we conducted an animal study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of a specific sub-strain, Lp3a, on FC. Methods: For the animal study, male Kunming mice were treated with doses of L. plantarum Lp3a ranging from 0.67 to 2.00 g/kg or an equivalent amount of placebo for 15 days prior to the induction of constipation via 20 mL/kg of 25% diphenoxylate solution. GI motility parameters including intestinal motion and stool amount were then assessed. In the human study, 120 patients with FC were randomized to treatment [L. plantarum Lp3a; 2×1.0×1010 (colony forming units; CFU) ×7 days] or control groups (n=60 each). The primary endpoint was survey information on FC signs/symptoms. Participants and observers were blinded to group allocation. A subset of 20 Lp3a treated patients underwent pre- and post-treatment 16 s ribosomal ribonucleic acid (rRNA) gene sequencing. Whole genome sequencing (WGS) of L. plantarum Lp3a was also performed. Results: Lp3a-treated mice showed significantly improved intestinal motion, reduced time to first defecation, and increased stool amounts. Similarly, patients in the treatment group (n=59) reported significant improvements in FC signs/symptoms compared to controls (n=58; all P<0.05). Although 16 s rRNA sequencing revealed no significant variations between pre- and post-treatment samples, WGS of Lp3a itself revealed several biological pathways that may underlie the relief of FC symptoms in animals and humans, including methane and fatty acid metabolism and bile acid biosynthesis. Conclusions: We found that the use of the novel probiotic sub-strain, L. plantarum Lp3a, led to clinically significant improvements in FC in both mice and humans, and identified the potential biological mechanisms underlying this activity.

20 August 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HWHui Wang
Hui Wang
ZXZhiyan Xu
Zhiyan Xu
ZXZiyue Xia
Ziyue Xia
MRMichael Rallo
Michael Rallo
ADAndrew Duffy
Andrew Duffy
MMMichael Matise
Michael Matise
In this study, we use molecular genetic approaches to clarify the role of the Hedgehog (Hh) pathway in regulating the blood–brain/spinal cord barrier (BBB) in the adult mouse central nervous system (CNS). Our work confirms and extends prior studies to demonstrate that astrocytes are the predominant cell type in the adult CNS that transduce Hh signaling, revealed by the expression of Gli1, a target gene of the canonical pathway that is activated in cells receiving Hh, and other key pathway transduction components. Gli1+ (Hh-responsive) astrocytes are distributed in specific regions of the CNS parenchyma, including layers 4/5/6 of the neocortex, hypothalamus, thalamus, and spinal cord, among others. Notably, although BBB properties in endothelial cells are normally regulated by both paracellular and transcellular mechanisms, conditional inactivation of Hh signaling in astrocytes results in transient, region-specific BBB defects that affect transcytosis but not paracellular diffusion. These findings stand in contrast to prior studies that implicated astrocytes as a source of Sonic hedgehog that limited extravasation via both mechanisms [J. I. Alvarez et al., Science 334, 1727–1731 (2011)]. Furthermore, using three distinct Cre driver lines as well as pharmacological approaches to inactivate Hh-pathway transduction globally in CNS astrocytes, we find that these specific BBB defects are only detected in the rostral hypothalamus and spinal cord but not the cortex or other regions where Gli1+ astrocytes are found. Together, our data show that Gli1+ Hh-responsive astrocytes have regionally distinct molecular and functional properties and that the pathway is required to maintain BBB properties in specific regions of the adult mammalian CNS. Significance Several signaling pathways have been implicated in regulating blood–brain/spinal cord barrier (BBB) properties in the adult mammalian central nervous system (CNS). However, it has become clear that the role of the Sonic hedgehog pathway has not been accurately defined. The current work addresses this issue by demonstrating that the pathway is required in protoplasmic astrocytes to maintain specific BBB characteristics in select regions of the CNS. In contrast to prior studies, we find that astrocytic, and not endothelial cell, Hedgehog signal transduction is required to maintain BBB properties through an effect on transcytosis but not paracellular diffusion. Our discovery raises the possibility that targeted inhibition of the pathway to achieve transient BBB permeability could be exploited for therapeutic purposes.

21 March 2017 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
HWHui Wang
Hui Wang
HGHongxing Gui
Hongxing Gui
MRMichael S. Rallo
Michael S. Rallo
ZXZhiyan Xu
Zhiyan Xu
MMMichael Matise
Michael Matise

13 June 2024 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
SSSoraya O. Sandoval
Soraya O. Sandoval
NMNatasha M. Méndez-Albelo
Natasha M. Méndez-Albelo
ZXZhiyan Xu
Zhiyan Xu
XZXinyu Zhao
Xinyu Zhao
Fragile X syndrome (FXS) is caused by epigenetic silencing of the X-linked fragile X messenger ribonucleoprotein 1 (FMR1) gene located on chromosome Xq27.3, which leads to the loss of its protein product, fragile X messenger ribonucleoprotein (FMRP). It is the most prevalent inherited form of intellectual disability and the highest single genetic cause of autism. Since the discovery of the genetic basis of FXS, extensive studies using animal models and human pluripotent stem cells have unveiled the functions of FMRP and mechanisms underlying FXS. However, clinical trials have not yielded successful treatment. Here we review what we have learned from commonly used models for FXS, potential limitations of these models, and recommendations for future steps.